Pelago Bioscience Acquires RG Discovery

Discovery Life Sciences Acquires ReachBio Research Labs

April 11, 2023

Biotechnology

Discovery Life Sciences has acquired Seattle-based ReachBio Research Labs to expand its cell biology, toxicology and drug screening capabilities. The acquisition strengthens Discovery's preclinical development and multi-omics service offering, enabling customers to access a broader set of predictive cell-based assays for hematologic diseases, immunology, oncology and cell & gene therapy programs.

Discovery Life Sciences Acquires AllCells

July 12, 2022

Biotechnology

Discovery Life Sciences has acquired AllCells to create an integrated, end-to-end provider of clinical-grade and RUO primary cell products and analytic services for the cell and gene therapy (CGT) continuum. The combined business — operating as AllCells, a Discovery Life Sciences Company and led by AllCells CEO Danny Zheng — aims to expand GMP-compliant starting materials, donor programs and multi‑omic characterization to accelerate CGT discovery through commercialization.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

Eurofins Scientific Acquires Beacon Discovery

February 18, 2021

Biotechnology

Eurofins Scientific has agreed to acquire Beacon Discovery, a San Diego–based drug discovery CRO specializing in GPCR research and compound libraries. The acquisition expands Eurofins Discovery’s integrated drug discovery capabilities, adding GPCR expertise and proprietary compound resources to support pharmaceutical and biotech clients. The transaction is expected to close in the coming weeks subject to customary conditions.

Genesis Drug Discovery & Development Acquires Comparative Biosciences (CBI)

August 5, 2020

Biotechnology

Genesis Drug Discovery & Development (GD3), a member of Genesis Biotechnology Group (GBG), has acquired Comparative Biosciences, Inc. (CBI), a Sunnyvale-based preclinical CRO. The acquisition adds GLP toxicology and safety pharmacology capabilities to GD3/GBG's integrated preclinical services, enabling end-to-end IND-enabling studies and expanding GD3's service offering.